Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15704720 | 0.81 | MEN1 (0.34) | — | |
| SCHEMBL15215946 | 0.79 | — | — | |
| SCHEMBL7785362 | 0.78 | BACE1 (0.38) | — | |
| SCHEMBL19939641 | 0.70 | KDM4E (0.32) | GAAALDH1A1 | |
| SCHEMBL12960364 | 0.68 | HRH4 (0.39) | GAAHTTSMN1; SMN2 | |
| SCHEMBL14582062 | 0.68 | METAP1 (0.36) | GAAHTTSMN1; SMN2 | |
| SCHEMBL24445584 | 0.67 | GAA (0.31) | GAAHTTSMN1; SMN2 | |
| SCHEMBL16079438 | 0.66 | GAA (0.30) | GAAHTTSMN1; SMN2 | |
| SCHEMBL16079434 | 0.65 | — | — | |
| SCHEMBL8796247 | 0.61 | TDP1 (0.34) | GAAHTTSMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9868711-B2 | Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders | BIOELECTRON TECHNOLOGY CORPORATION (US) | 2018-01-16 | — | — | US | disclosed |
| US-20160228491-A1 | THERAPEUTIC COMPOSITIONS INCLUDING PHENAZINE-3-ONE AND PHENOTHIAZINE-3-ONE DERIVATIVES AND USES THEREOF | STEALTH PEPTIDES INTERNATIONAL, INC. (MC) | 2016-08-11 | — | — | US | disclosed |
| US-20160039776-A1 | PHENAZINE-3-ONE AND PHENOTHIAZINE-3-ONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISORDERS | PTC THERAPEUTICS, INC. | 2016-02-11 | — | — | US | disclosed |
| US-20140275045-A1 | PHENAZINE-3-ONE AND PHENOTHIAZINE-3-ONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISORDERS | EDISON PHARMACEUTICALS, INC. (US) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275045-A1 | PHENAZINE-3-ONE AND PHENOTHIAZINE-3-ONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISORDERS | PCK2, MGST3, TXNRD2 | GAA 463/4885HTT 80/4885SMN1; SMN2 552/4885 |
| US-20160039776-A1 | PHENAZINE-3-ONE AND PHENOTHIAZINE-3-ONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISORDERS | PCK2, MGST3, TXNRD2 | GAA 463/4885HTT 80/4885SMN1; SMN2 552/4885 |
| US-20160228491-A1 | THERAPEUTIC COMPOSITIONS INCLUDING PHENAZINE-3-ONE AND PHENOTHIAZINE-3-ONE DERIVATIVES AND USES THEREOF | TYR, DNPEP, ARG2 | GAA 1344/4885HTT 19/4885SMN1; SMN2 2480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.